

SmartPA Criteria Proposal

Drug/Drug Class:	Psoriasis Agents, Topical PDL Edit
First Implementation Date:	May 7, 2008
Proposed Date:	July 18, 2023
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Psoriasis is a chronic, inflammatory, non-contagious, genetic, immune-mediated, dermatologic condition. Plaque psoriasis is the most common form of psoriasis, affecting 80 to 90% of psoriasis patients. The plaques present as raised, inflamed, scaly patches of skin that may also be itchy and painful. Plaques can be present anywhere on the body, but most often occur on the scalp, knees, elbows, and torso.. Psoriasis affects approximately 7.5 million Americans; presentation can occur at any age, but typically occurs between the ages of 15 to 25 years. Psoriasis can range from mild to severe disease and can lead to low self-esteem and depression. During the disease process there is hyperproliferation and abnormal differentiation of the psoriatic epidermis. Mild plaque psoriasis can often be managed with topical therapies, while moderate to severe disease may require phototherapy or systemic management. Moderate to severe disease is typically defined as 5 to 10% of body surface area involvement; involvement of the face, palm, or sole; or disease that is otherwise disabling.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Calcipotriene Crm/Oint/Soln 	<ul style="list-style-type: none"> Calcipotriene Foam Calcipotriene/Betamethasone Calcitriol Duobrii® Enstilar® Sorilux® Taclonex® Vtama® Zoryve™

Type of Criteria: ☐ Increased risk of ADE
☐ Appropriate Indications

☒ Preferred Drug List
☐ Clinical Edit

Data Sources: ☐ Only Administrative Databases

☒ Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Psoriasis Agents, Topical
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- For non-preferred agents:
 - Failure to achieve desired therapeutic outcomes with trial on 1 or more preferred agents **in the past 6 months:**
 - Documented trial period of preferred agents **OR**
 - Documented ADE/ADR to preferred agents **AND**
 - **For Vtama and Zoryve:**
 - **Prescribed by or in consultation with a rheumatologist or dermatologist AND**
 - **Documented diagnosis of plaque psoriasis AND**
 - **Documented body surface area (BSA) involvement $\geq 2\%$ and $\leq 20\%$ AND**
 - **Failure to achieve desired therapeutic outcomes with trial on 1 or more non-preferred agents unlike Vtama or Zoryve in the past 6 months**
 - **For Zoryve: Participant is aged ≥ 12 years**
 - **For Vtama:**
 - **Participant is aged ≥ 18 years AND**
 - **Failure to achieve desired therapeutic outcomes with trial on Zoryve in the past 6 months**

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met
- Claim exceeds maximum dosing limitation for the following:

Drug Description	Generic Equivalent	Max Dosing Limitation
DUOBRII 0.01%-0.045% LOT	HALOBETASOL/TAZAROTENE	2 TUBES EVERY 28 DAYS
VTAMA 1% CREAM	TAPINAROF	1 TUBE EVERY 28 DAYS
ZORYVE 0.3% CREAM	ROFLUMILAST	1 TUBE EVERY 28 DAYS

Required Documentation

Laboratory Results: ☐
MedWatch Form: ☐

Progress Notes: ☐
Other: ☐

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

- Evidence-Based Medicine and Fiscal Analysis: “Therapeutic Class Review: DERMATOLOGIC AGENTS: Topical Agents for Psoriasis”, Gainwell Technologies; Last updated April 3, 2023.
- Evidence-Based Medicine Analysis: “Topical Psoriasis Agents”, UMKC-DIC; October 2022.
- USPDI, Micromedex; 2023.
- Clinical Pharmacology [online]. Tampa (FL): Elsevier. 2023.

DRAFT